About
This medication represents a triple combination therapy designed for the comprehensive management of Type 2 Diabetes Mellitus. It combines glimepiride, a sulfonylurea; metformin, a biguanide; and vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glimepiride stimulates the pancreatic beta cells to release insulin, directly lowering blood glucose. Metformin acts by reducing glucose production in the liver, decreasing glucose absorption from the gut, and enhancing insulin sensitivity in peripheral tissues. Vildagliptin works by inhibiting the enzyme DPP-4, which prolongs the action of incretin hormones, leading to glucose-dependent increases in insulin secretion and suppression of glucagon release. This multi-pronged approach targets different pathophysiological defects in Type 2 Diabetes, providing robust glycemic control for patients inadequately controlled on dual therapy or requiring intensive management.
Uses
- Intensive management of Type 2 Diabetes.
- When dual therapy is insufficient.
- To achieve optimal blood sugar targets.
- As an adjunct to diet and exercise.
Directions For Use
Take orally with meals, usually once or twice daily, as directed by your physician. Do not chew or crush.
Benefits
- Comprehensive blood glucose control.
- Multiple complementary mechanisms of action.
- Improved pancreatic beta-cell function.
- Reduced risk of hyperglycemia.
- Potential for sustained glycemic benefits.
- Convenient single-tablet regimen.
Side Effects
- Hypoglycemia (low blood sugar)
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Metallic taste
- Nasopharyngitis
- Lactic acidosis (rare, serious)
- Pancreatitis (rare)
- Joint pain
- Skin rash
Safety Measures
- Alcohol - Avoid excessive alcohol consumption due to increased risk of hypoglycemia and lactic acidosis.
- Pregnancy - Not recommended during pregnancy due to insufficient safety data. Insulin is generally preferred.
- Breastfeeding - Metformin passes into breast milk; data for glimepiride and vildagliptin are limited. Use with caution and medical advice.
- Liver - Contraindicated in patients with hepatic impairment due to vildagliptin component and increased risk of lactic acidosis.
- Kidney - Contraindicated in severe renal impairment due to metformin. Dose adjustment needed for moderate impairment.
- Lung - Use with caution in severe respiratory conditions that may predispose to hypoxia and lactic acidosis.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!